The present disclosure relates to compositions and methods relating to the
characterization and function of CCR6. Specifically, the present
disclosure provides transgenic animals comprising disruptions in a CCR6
gene and methods of treating diseases conditions, such as pain,
inflammatory bowel disease, rheumatoid arthritis and contact dermatitis.
The present disclosure further relates to agents that modulate CCR6 and
methods of screening for agents that modulate CCR6 for the treatment of
diseases and conditions such as pain, inflammatory bowel disease,
rheumatoid arthritis and contact dermatitis.